StockCIK 1819790

Tarsus Pharmaceuticals, Inc. (TARS): Insider Trades and Fund Holdings

In the past 12 months, Tarsus Pharmaceuticals, Inc. insiders reported 0 open-market purchases worth $0 and 9 sales worth $5.19M; 9 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months

$0Bought by insiders, 12 months

$5.19MSold by insiders, 12 months

1Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 17, 2026.

Recent TARS insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Sep 17	Sep 15	William J. Phd LinkDirector	Director	▼ SELL10b5-1	12,500	78.38	$980K	−12%	Form 4 ↗
Sep 9	Sep 4	Elizabeth Yeu LinChief Medical Officer	Chief Medical Officer	▼ SELL10b5-1	10,773	87.50	$943K	−81%	Form 4 ↗
Sep 9	Sep 4	Bobak R. AzamianCEO	CEO (ind.)	▼ SELL10b5-1	10,000	90.56	$906K	−1.2%	Form 4 ↗
Sep 9	Sep 4	Seshadri NeervannanCOO	COO	▼ SELL10b5-1	4,564	85.00	$388K	−5.5%	Form 4 ↗
Sep 9	Sep 4	Elizabeth Yeu LinChief Medical Officer	Chief Medical Officer (ind.)	▼ SELL10b5-1	3,180	87.50	$278K	−67%	Form 4 ↗
Sep 3	Sep 2	Bobak R. AzamianCEO	CEO (ind.)	▼ SELL10b5-1	10,000	80.06	$801K	−1.2%	Form 4 ↗
Sep 3	Sep 2	Elizabeth Yeu LinChief Medical Officer	Chief Medical Officer	▼ SELL10b5-1	5,387	80.00	$431K	−29%	Form 4 ↗
Sep 3	Sep 1	Elizabeth Yeu LinChief Medical Officer	Chief Medical Officer	▼ SELL10b5-1	4,601	73.86	$340K	−20%	Form 4 ↗
Sep 3	Sep 2	Elizabeth Yeu LinChief Medical Officer	Chief Medical Officer (ind.)	▼ SELL10b5-1	1,590	80.00	$127K	−25%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

Insider	Role	Bought	Sells	Sold	Latest
William J. Phd Link	Director	$0	1	$980K	Sep 17, 2026
Elizabeth Yeu Lin	Chief Medical Officer	$0	5	$2.12M	Sep 9, 2026
Bobak R. Azamian	CEO	$0	2	$1.71M	Sep 9, 2026
Seshadri Neervannan	COO	$0	1	$388K	Sep 9, 2026

Tracked funds that report TARS

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Renaissance Technologies	Q2 2026	9,300	$585K	0.00%	▼ −87.3%

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →